| Title: |
Humoral Immunity and Antibody Responses against Diphtheria, Tetanus, and Pneumococcus after Immune Effector Cell Therapies: A Prospective Study |
| Authors: |
Georgios Angelidakis, Roy F. Chemaly, Pranoti V. Sahasrabhojane, Oscar Morado-Aramburo, Ying Jiang, Micah M. Bhatti, Elizabeth Shpall, Chitra Hosing, Preetesh Jain, Kris Michael Mahadeo, Fareed Khawaja, Peter Elhajj, Jennifer A. Wargo, Robert R. Jenq, Nadim J. Ajami, Partow Kebriaei, Ella J. Ariza-Heredia |
| Source: |
Vaccines, Vol 12, Iss 9, p 1070 (2024) |
| Publisher Information: |
MDPI AG, 2024. |
| Publication Year: |
2024 |
| Collection: |
LCC:Medicine |
| Subject Terms: |
tetanus, diphtheria, pneumococcus, immune effector cell therapies, humoral immunity, CAR-T, Medicine |
| More Details: |
Patients undergoing immune effector cell therapy (IECT) are at high risk for infections. We assessed seropositivity against pneumococcus, tetanus, and diphtheria in patients before and after IECT and the patients’ response to vaccination. We enrolled patients who underwent IECT from January 2020 to March 2022. Antibody levels for diphtheria, tetanus, and pneumococcus were measured before IECT, at 1 month, and 3–6 months after. Eligible patients were vaccinated after IECT. In non-seroprotected patients, we discontinued testing. Before IECT, most patients had seroprotective antibody levels against tetanus (68/69, 99%) and diphtheria (65/69, 94%), but fewer did against pneumococcus (24/67, 36%). After IECT, all patients had seroprotective antibody levels for tetanus at 1 month (68/68) and 3–6 months (56/56). For diphtheria, 65/65 patients (100%) had seroprotective antibody levels at 1 month, and 48/53 (91%) did at 3–6 months. For pneumococcus, seroprotective antibody levels were identified in 91% (21/23) of patients at 1 month and 79% (15/19) at 3–6 months following IECT. Fifteen patients received a pneumococcal vaccine after IECT, but none achieved seroprotective response. One patient received the tetanus-diphtheria vaccine and had a seroprotective antibody response. Because some patients experience loss of immunity after IECT, studies evaluating vaccination strategies post-IECT are needed. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2076-393X |
| Relation: |
https://www.mdpi.com/2076-393X/12/9/1070; https://doaj.org/toc/2076-393X |
| DOI: |
10.3390/vaccines12091070 |
| Access URL: |
https://doaj.org/article/b2bd91b9270a46a1a6315748347f8e51 |
| Accession Number: |
edsdoj.b2bd91b9270a46a1a6315748347f8e51 |
| Database: |
Directory of Open Access Journals |
